

Ken Ogasawara

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4437798/ken-ogasawara-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

45
papers

1,528
citations

19
h-index

38
g-index

52
ext. papers

2,256
ext. citations

5.4
avg, IF

4.36
L-index

#	Paper	IF	Citations
45	Outreach: Results from a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) Administered As Inpatient (Inpt) or Outpatient (Outpt) Treatment in the Nonuniversity Setting in Patients (Pts) with R/R Large B-Cell Lymphoma (LBCL). <i>Blood</i> , 2021 , 138, 1762-1762	2.2	0
44	Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL). <i>Blood</i> , 2021 , 138, 2840-2840	2.2	5
43	Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL): Results from the Randomized Phase 3 Transform	2.2	15
42	Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. <i>Blood</i> , 2021 ,	2.2	13
41	Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants. <i>Cancer Chemotherapy and Pharmacology</i> , 2021 , 88, 369-377	3.5	1
40	Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 1621-1633	6.2	5
39	Evaluation of the Potential for QTc Prolongation With Repeated Oral Doses of Fedratinib in Patients With Advanced Solid Tumors. <i>Clinical Pharmacology in Drug Development</i> , 2021 , 10, 366-375	2.3	2
38	Recurrent or progressive pediatric brain tumors: population pharmacokinetics and exposure-response analysis of pomalidomide. <i>Pediatric Research</i> , 2021 , 90, 832-839	3.2	0
37	Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach. <i>Cancer Chemotherapy and Pharmacology</i> , 2021 , 88, 941-952	3.5	4
36	Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 86, 87-95	3.5	4
35	Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 85, 899-906	3.5	11
34	A phase I study of the effect of repeated oral doses of pantoprazole on the pharmacokinetics of a single dose of fedratinib in healthy male subjects. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 85, 995-1001	3.5	3
33	Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in 3 Ongoing Clinical Studies in Relapsed/Refractory (R/R) Large B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Noneligible (TNE) Patients: Transcend NHL 001, Outreach, and PILOT. <i>Biology of Blood</i>	4.7	2
32	Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). <i>Blood</i> , 2020 , 136, 39-40	2.2	23
31	Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 85, 1109-1117	3.5	2
30	Excretion balance and pharmacokinetics following a single oral dose of [C]-fedratinib in healthy subjects. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 86, 307-314	3.5	4
29	Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. <i>Lancet, The</i> , 2020 , 396, 839-852	40	387

28	Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 217-227	6.2	10
27	Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 84, 891-898	3.5	15
26	Drug-Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC-122) in Healthy Adult Subjects. <i>Journal of Clinical Pharmacology</i> , 2019 , 59, 1620-1631	2.9	4
25	Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Ineligible Patients: Transcend NHL 001, Outreach, and PILOT. <i>Blood</i> , 2019 , 134, 2868-2868	2.2	10
24	Clinical Development of Biologics Approved by the US Food and Drug Administration, 2003-2016. <i>Therapeutic Innovation and Regulatory Science</i> , 2019 , 53, 752-758	1.2	3
23	Use of Population Pharmacokinetic Analyses Among FDA-Approved Biologics. <i>Clinical Pharmacology in Drug Development</i> , 2019 , 8, 914-921	2.3	3
22	Exposure- and Dose-response Analyses in Dose Selection and Labeling of FDA-approved Biologics. <i>Clinical Therapeutics</i> , 2018 , 40, 95-102.e2	3.5	12
21	Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver. <i>Molecular Pharmaceutics</i> , 2018 , 15, 2621-2632	5.6	45
20	Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 79, 1169-1177	3.5	30
19	Multiplex and Label-Free Relative Quantification Approach for Studying Protein Abundance of Drug Metabolizing Enzymes in Human Liver Microsomes Using SWATH-MS. <i>Journal of Proteome Research</i> , 2017 , 16, 4134-4143	5.6	25
18	Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 78, 281-8	3.5	42
17	Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 76, 1143-52	3.5	58
16	Pharmacokinetics of total and unbound prednisone and prednisolone in stable kidney transplant recipients with diabetes mellitus. <i>Therapeutic Drug Monitoring</i> , 2014 , 36, 448-55	3.2	9
15	Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients. <i>Clinical Pharmacokinetics</i> , 2013 , 52, 751-62 ²	6.2	59
14	Concentration of tacrolimus and major metabolites in kidney transplant recipients as a function of diabetes mellitus and cytochrome P450 3A gene polymorphism. <i>Xenobiotica</i> , 2013 , 43, 641-9	2	11
13	Mycophenolic acid glucuronide is transported by multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine, tacrolimus or sirolimus. <i>Xenobiotica</i> , 2013 , 43, 229-35	2	31
12	Hepatitis C virus-related cirrhosis is a major determinant of the expression levels of hepatic drug transporters. <i>Drug Metabolism and Pharmacokinetics</i> , 2010 , 25, 190-9	2.2	58
11	Identification of multidrug and toxin extrusion (MATE1 and MATE2-K) variants with complete loss of transport activity. <i>Journal of Human Genetics</i> , 2009 , 54, 40-6	4.3	71

10	Impact of regulatory polymorphisms in organic anion transporter genes in the human liver. <i>Pharmacogenetics and Genomics</i> , 2009 , 19, 647-56	1.9	19
9	Adaptive responses of renal organic anion transporter 3 (OAT3) during cholestasis. <i>American Journal of Physiology - Renal Physiology</i> , 2008 , 295, F247-52	4.3	31
8	Kidney-specific expression of human organic cation transporter 2 (OCT2/SLC22A2) is regulated by DNA methylation. <i>American Journal of Physiology - Renal Physiology</i> , 2008 , 295, F165-70	4.3	66
7	Analysis of regulatory polymorphisms in organic ion transporter genes (SLC22A) in the kidney. <i>Journal of Human Genetics</i> , 2008 , 53, 607-614	4.3	37
6	Hepatocyte nuclear factor-4{alpha} regulates the human organic anion transporter 1 gene in the kidney. <i>American Journal of Physiology - Renal Physiology</i> , 2007 , 292, F1819-26	4.3	46
5	Critical roles of Sp1 in gene expression of human and rat H+/organic cation antiporter MATE1. <i>American Journal of Physiology - Renal Physiology</i> , 2007 , 293, F1564-70	4.3	35
4	Characterization of the Basal promoter element of human organic cation transporter 2 gene. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007 , 321, 684-9	4.7	17
3	Human organic anion transporter 3 gene is regulated constitutively and inducibly via a cAMP-response element. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006 , 319, 317-22	4.7	32
2	Pharmacokinetic significance of renal OAT3 (SLC22A8) for anionic drug elimination in patients with mesangial proliferative glomerulonephritis. <i>Pharmaceutical Research</i> , 2005 , 22, 2016-22	4.5	34
1	Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. <i>Circulation</i> , 1997 , 95, 2032-6	16.7	205